PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Kavanaugh, Arthur
TI  - Apremilastin Patients with Psoriatic Arthritis: Results of the PALACE-1 Trial
DP  - 2012  01
TA  - MD Conference Express
PG  - 19--19
VI  - 12
IP  - 19
4099  - http://mdc.sagepub.com/content/12/19/19.short
4100  - http://mdc.sagepub.com/content/12/19/19.full
AB  - In PALACE-1 trial apremilast, an oral phosphodiesterase 4 inhibitor, was shown to be safe and effective in treating psoriatic arthritis (PsA) in subjects previously exposed to disease-modifying antirheumatic drugs. Apremilast modulates the production of pro- (tumor necrosis factor-a, natural killer cells, and epidermal keratinocytes) and anti-inflammatory mediators (interleukin-10), including those implicated in the etiopathogenesis of PsA.